In this prospective observational study, we sought to compare the efficacy and safety of docetaxel + oxaliplatin + capecitabine (DOC) with epirubicin + oxaliplatin + 5-fluouracil (EOF) as neoadjuvant chemotherapy (NAC) for clinical T3 or T4 non-metastatic gastric cancer (GC) patients.

Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer / Petrioli, Roberto; Marrelli, Daniele; Roviello, Franco; D'Ignazio, Alessia; Torre, Pamela; Chirra, Martina; Savelli, Vinno; Ambrosio, Maria Raffaella; Francini, Guido; Calomino, Natale; Farsi, Marco; Vernillo, Remo; Francini, Edoardo. - In: SURGICAL ONCOLOGY. - ISSN 1879-3320. - 32:(2019), pp. 2-7. [10.1016/j.suronc.2019.10.002]

Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer

Francini, Edoardo
2019

Abstract

In this prospective observational study, we sought to compare the efficacy and safety of docetaxel + oxaliplatin + capecitabine (DOC) with epirubicin + oxaliplatin + 5-fluouracil (EOF) as neoadjuvant chemotherapy (NAC) for clinical T3 or T4 non-metastatic gastric cancer (GC) patients.
2019
5-Fluorouracil; Capecitabine; Docetaxel; Gastric cancer; NAC; Neoadjuvant; Oxaliplatin
01 Pubblicazione su rivista::01a Articolo in rivista
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer / Petrioli, Roberto; Marrelli, Daniele; Roviello, Franco; D'Ignazio, Alessia; Torre, Pamela; Chirra, Martina; Savelli, Vinno; Ambrosio, Maria Raffaella; Francini, Guido; Calomino, Natale; Farsi, Marco; Vernillo, Remo; Francini, Edoardo. - In: SURGICAL ONCOLOGY. - ISSN 1879-3320. - 32:(2019), pp. 2-7. [10.1016/j.suronc.2019.10.002]
File allegati a questo prodotto
File Dimensione Formato  
Francini_Gastric-cancer.pdf

Open Access dal 24/12/2020

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 434.07 kB
Formato Adobe PDF
434.07 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1343741
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact